Naproxen

Mechanism

Ketorolac outweighs other NSAIDs in antiplatelet and ulcerogenic effect. Its label places treatment with aspirin or other NSAIDs, selective COX-2 inhibitors included, among the contraindications, and the interactions section states it must not be used with other NSAIDs because of the increased rate of serious class adverse effects: gastrointestinal bleeding and perforation, renal injury, and bleeding from platelet inhibition. Analgesia does not improve when the second drug is added, since the target is the same enzyme family – cyclooxygenase.

Symptoms

Black or tarry stools, coffee-ground vomit, epigastric pain, sudden weakness and pallor from anaemia. Falling urine output and swelling as a sign of renal injury. In older people and those with a history of ulcer the picture may begin with the bleed itself, without preceding pain.

Management

The combination is taken apart: one NSAID remains. For severe pain that is usually ketorolac in a short course within the label limit, with the rest of the analgesia covered by paracetamol, metamizole or an opioid. Gastroprotection with a proton pump inhibitor does not lift the contraindication. After a ketorolac dose, another NSAID is not added until its action ends, not merely until the next scheduled dose.

Mechanism

Aspirin and naproxen are both NSAIDs: together they damage the stomach lining more and cause ulcers and bleeding more often (aspirin 100 mg and naproxen SmPCs). Naproxen taken for more than one day in a row also blunts the antiplatelet effect of low-dose aspirin, and this can last several days after naproxen is stopped; the Spanish SmPC calls its clinical relevance unknown (naproxen SmPC). In a study cited in the US naproxen label (FDA), the interaction was stronger when naproxen was taken 30 minutes before aspirin and most marked in the first days after naproxen was stopped.

Symptoms

Black tarry stools, vomiting blood, abdominal pain, weakness, dizziness and cold sweat are signs of gastrointestinal bleeding. Bruising, bleeding gums and nosebleeds are less common. The weaker antiplatelet effect of aspirin causes no symptoms by itself, but in patients with high cardiovascular risk it can reduce the cardiovascular protection aspirin gives.

Management

The naproxen SmPC contraindicates naproxen with other NSAIDs and asks for special caution with low-dose aspirin (naproxen SmPC). Avoid NSAIDs with aspirin whenever possible (aspirin 100 mg SmPC). The FDA does not generally recommend naproxen with analgesic doses of aspirin because of bleeding risk. For patients on low-dose aspirin for cardioprotection who need occasional pain relief, the FDA advises an NSAID that does not interfere with aspirin or a non-NSAID analgesic; naproxen is not a substitute for low-dose aspirin (US naproxen label). If naproxen is still needed with low-dose aspirin, consider gastroprotection with misoprostol or a proton pump inhibitor (naproxen SmPC) and watch for signs of bleeding (US naproxen label).

Mechanism

This pair has two mechanisms. The first is additive bleeding risk. Naproxen inhibits platelet aggregation, prolongs bleeding time and can cause ulcers and bleeding in the stomach and gut (naproxen SmPC), while apixaban blocks clotting factor Xa. Together they raise the bleeding risk (apixaban SmPC of the European Medicines Agency, EMA). The second is pharmacokinetic: naproxen inhibits the P-glycoprotein transporter that clears apixaban. A single 500 mg dose of naproxen raised the apixaban area under the curve (AUC) 1.5-fold and peak concentration 1.6-fold. Bleeding time did not change in a clinically relevant way in that study, and this kinetic effect needs no apixaban dose change (apixaban SmPC, EMA).

Symptoms

Black, tarry stools (melena), vomiting blood or coffee-ground material, upper abdominal pain. Other bleeding can occur: bruising without trauma, nosebleeds, blood in the urine. Risk is higher in older patients, after a previous ulcer and at higher naproxen doses (naproxen SmPC).

Management

Avoid non-steroidal anti-inflammatory drugs (NSAIDs) in a patient on an anticoagulant when they are not needed: the European Society of Cardiology (ESC) advises offering other pain relief or disease-modifying treatment (ESC 2024). If naproxen is still needed, use the lowest effective dose for the shortest time (naproxen SmPC) and give apixaban with caution during that period (apixaban SmPC of the European Medicines Agency, EMA). For older patients and those with a previous ulcer, the naproxen SmPC recommends gastroprotection with misoprostol or a proton pump inhibitor, and suggests considering it when other drugs raise the risk of gastrointestinal bleeding (naproxen SmPC). The ESC advises a proton pump inhibitor when gastrointestinal bleeding risk is high (ESC 2024). Apixaban is contraindicated with an active or recent gastrointestinal ulcer (apixaban SmPC, EMA). Naproxen is contraindicated with active or recurrent peptic ulcer or bleeding and after previous NSAID-related bleeding, and is not recommended with creatinine clearance below 30 mL/min (naproxen SmPC). During NSAID use, the European Heart Rhythm Association (EHRA) suggests an extra blood test: haemoglobin, kidney and liver function (EHRA 2021). Stop naproxen at once if gastrointestinal bleeding or an ulcer occurs (naproxen SmPC), and also stop apixaban in severe bleeding (apixaban SmPC, EMA).

Mechanism

Both are NSAIDs blocking the same enzyme, so analgesia does not add up the way harm does. The ibuprofen label is blunt: simultaneous use with other NSAIDs should be avoided, since it can increase the risk of gastrointestinal ulcer and bleeding. Naproxen's long half-life keeps inhibition running for hours after the last dose, so the overlap is real even with spaced dosing.

Symptoms

Black or tarry stools, coffee-ground vomit, epigastric pain that food does not settle. Ankle oedema, reduced urine output, rising blood pressure and creatinine follow. Over 65, with prior ulcer, anticoagulants or corticosteroids, bleeding may be the first sign.

Management

Keep a single NSAID. If naproxen is not enough, reinforce with paracetamol or metamizole rather than adding ibuprofen. If both have already been taken, stop one and keep gastric protection where risk factors exist; black stools or coffee-ground vomit call for urgent assessment.

Mechanism

Contrast and NSAID (naproxen) – additive nephrotoxicity, especially in chronic kidney disease and dehydration.

Symptoms

Reduced urine output, rising creatinine and potassium, oedema. Symptoms appear earlier in older patients and chronic kidney disease.

Management

Stop naproxen 48 hours before planned contrast and resume 48 hours after with stable renal function. Alternative analgesic: paracetamol. Provide contrast nephroprotection with adequate saline hydration.

Mechanism

NSAIDs reduce renal lithium clearance via prostaglandin-dependent renal blood flow blockade. Lithium plasma levels rise 1.5- to 2-fold with toxicity risk.

Symptoms

Tremor, muscle twitching, nausea, diarrhoea, confusion, ataxia. Symptoms emerge when serum lithium exceeds 1.2 mmol/L.

Management

Avoid prolonged combination. If naproxen is needed for a short course, reduce lithium by 25–30% and check lithium level at 5–7 days. For chronic analgesia: paracetamol or celecoxib (with lithium monitoring).

Mechanism

Naproxen, like other prostaglandin synthesis inhibitors, reduces methotrexate clearance and may increase its toxicity (naproxen SmPC). With high-dose methotrexate, NSAID co-administration produced high and prolonged methotrexate levels, up to fatal haematological and gastrointestinal toxicity (AEMPS and FDA methotrexate labels). Naproxen has a half-life of 12–17 hours (FDA label), so its effect lasts longer than that of short half-life NSAIDs.

Symptoms

Mucositis, leukopenia, thrombocytopenia, rising creatinine within 1–2 weeks.

Management

With high-dose methotrexate (oncology regimens, e.g. osteosarcoma), do not give naproxen before or during administration; the AEMPS and FDA methotrexate labels state this directly and give no washout interval. With low-dose methotrexate (rheumatology, psoriasis), the combination may be used with caution: monitor full blood count and renal function, especially if the two are taken less than 24 hours apart. With impaired renal function, including mild impairment, the combination is not recommended (methotrexate SmPCs, including EMA).

Mechanism

Direct oral anticoagulant (rivaroxaban) + NSAID (naproxen) – additive GI bleeding risk.

Symptoms

Black or tarry stools, vomiting blood, epigastric pain. Risk multiplies in older patients and with prior peptic ulcer disease.

Management

Avoid prolonged combination. If naproxen is needed for a short course, use the minimum effective dose for 5–7 days under pantoprazole cover. For chronic analgesia: paracetamol or celecoxib.

Mechanism

NSAID (naproxen) + nephrotoxic calcineurin inhibitor (tacrolimus) – additive acute kidney injury risk in transplant patients.

Symptoms

Reduced urine output, rising creatinine and potassium, oedema. Symptoms appear earlier in older patients and chronic kidney disease.

Management

Avoid prolonged combination. For post-transplant analgesia: paracetamol (up to 2 g/day) or a short opioid course. For neuropathic pain: gabapentin or pregabalin.

Mechanism

Naproxen (NSAID) inhibits platelet aggregation and injures the gastric mucosa. On warfarin, GI bleeding risk multiplies, particularly in older patients and with prior peptic ulcer disease.

Symptoms

Gum bleeding, epistaxis, bruising without trauma, blood in urine or stool, menorrhagia. Severe cases include gastrointestinal or intracranial haemorrhage. Risk rises in patients over 65 and with prior peptic ulcer disease.

Management

Avoid chronic naproxen on warfarin. For analgesia, choose paracetamol. For chronic NSAID needs, use a selective COX-2 inhibitor (celecoxib) under pantoprazole cover.

Mechanism

NSAIDs weaken amlodipine's antihypertensive effect via renal prostaglandin suppression.

Symptoms

Gradual blood pressure rise 1–2 weeks after starting naproxen. In chronic kidney disease: fluid retention and oedema risk.

Management

For short naproxen courses (5–7 days), monitor blood pressure. For chronic analgesia: switch to paracetamol or celecoxib (with PPI cover).

Mechanism

NSAIDs weaken the antihypertensive effect of beta-blockers via renal prostaglandin suppression.

Symptoms

Gradual blood pressure rise 1–2 weeks after starting the NSAID. In chronic kidney disease: risk of fluid retention and oedema.

Management

For short naproxen courses (5–7 days), monitor blood pressure. For chronic analgesia: switch to paracetamol or celecoxib (with PPI cover).

Mechanism

Naproxen acts on peripheral cyclooxygenase and has a long half-life, allowing twice-daily dosing; paracetamol works centrally. They share no relevant elimination pathway and do not displace each other from albumin, and the naproxen label reserves its combination warning for other NSAIDs and acetylsalicylic acid.

Symptoms

The pair produces no distinct picture. Naproxen keeps a high gastrointestinal risk because of its long half-life: epigastric pain, dyspepsia, black stools, plus fluid retention and rising blood pressure. Paracetamol adds hepatic risk only above the daily dose.

Management

The combination is acceptable in acute pain and in joint pain when naproxen alone is not enough. Keep a single NSAID, watch blood pressure in hypertensive patients, and consider gastric protection over age 65 or with a history of ulcer.